ARMO BioSciences, Inc. (Armo)

Oncology Corporate Profile

Stock Performance


HQ Location

575 Chesapeake Drive
Redwood City, CA 94063

Company Description

ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary products that activate the immune system of cancer patients to recognize and eradicate tumors. The Company’s lead product candidate, AM0010 (pegilodecakin), stimulates the survival, expansion and killing (cytotoxic) potential of a particular type of white blood cell in the immune system called CD8+ T cells. CD8+ T cells recognize and kill cancer cells and an increased presence of intra-tumoral CD8+ T cells may result in improved prognosis and survival in patients.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
AM0010PEG-IL-10Non Small Cell Lung Cancer (NSCLC)I
AM0010PEG-IL-10Renal cell carcinoma (RCC)I
AM0010PEG-IL-10Various cancer typesI

View additional information on product candidates here »


Recent News Headlines

There are no news items to display